Furthermore, clinical studies have revealed that Lcn2 levels in plasma and cerebrospinal fluid can be used as biomarkers for Alzheimer’s disease and other neurodegenerative dementias (Eruysal et al., 2019; Llorens et al., 2020). This evidence concerns the gene LCN2 and Alzheimer disease.